Diamyd Medical enters agreement for intralymphatic Diamyd® trial in LADA

The agreement with the Norwegian University of Science and Technology in Trondheim (NTNU) refers to a first,  investigator initiated clinical Phase II trial with the diabetes vaccine Diamyd® administered directly into the lymph node in a limited number of patients newly diagnosed with LADA (Latent Autoimmune Diabetes in Adults).“NTNU has long experience from trials in LADA”, says Ulf Hannelius, CEO of Diamyd Medical. “We are pleased that NTNU wants to use intralymphatic Diamyd[®] in this interesting patient group. The trial lays the foundation for a valuable broadening of our platform based